Role of environmental toxins in endemic (Balkan) nephropathy

被引:116
作者
Grollman, Arthur P. [1 ]
Jelakovic, Bojan
机构
[1] SUNY Stony Brook, Dept Pharmacol Sci, Biol Chem Lab, Stony Brook, NY 11794 USA
[2] Univ Zagreb, Sch Med, Dept Nephrol & Arterial Hypertens, Zagreb 41001, Croatia
[3] Univ Hosp Ctr, Zagreb, Croatia
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2007年 / 18卷 / 11期
关键词
D O I
10.1681/ASN.2007050537
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
An international symposium, held in Zagreb, Croatia, in October 2006, brought together basic scientists and clinical investigators engaged in research on endemic (Balkan) nephropathy, a chronic renal tubulointerstitial disease of previously unknown cause that often is accompanied by upper urinary tract urothelial cancer. Although this disease is endemic in rural areas of Bosnia, Bulgaria, Croatia, Romania, and Serbia, a similar clinical entity occurs throughout Europe, Asia, and North America. Recent advances in the understanding of endemic nephropathy now favor the causative role of aristolochic acid over the ubiquitous mycotoxin known as ochratoxin A. Specifically, aristolactam-DNA adducts have been found in renal tissues and urothelial cancers of affected patients. A "signature" p53 mutation in the upper urothelial cancer associated with this disease provides evidence of long-term exposure to aristolochic acid. In addition, the renal pathophysiology and histopathology observed in endemic nephropathy most closely resemble the entity known as aristolochic acid nephropathy. Public health authorities in countries harboring this disease are encouraged to reduce the potential for dietary exposure to Aristolochia clematitis.
引用
收藏
页码:2817 / 2823
页数:7
相关论文
共 43 条
[31]   Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). [J].
Nortier, JL ;
Martinez, MM ;
Schmeiser, HH ;
Arlt, VM ;
Bieler, CA ;
Petein, M ;
Depierreux, MF ;
De Pauw, L ;
Abramowicz, D ;
Vereerstraeten, P ;
Vanherweghem, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (23) :1686-1692
[32]   The IARC TP53 database: New Online mutation analysis and recommendations to users [J].
Olivier, M ;
Eeles, R ;
Hollstein, M ;
Khan, MA ;
Harris, CC ;
Hainaut, P .
HUMAN MUTATION, 2002, 19 (06) :607-614
[33]   Ochratoxin A-induced mutagenesis in mammalian cells is consistent with the production of oxidative stress [J].
Palma, Nieves ;
Cinelli, Serena ;
Sapora, Orazio ;
Wilson, Samuel H. ;
Dogliotti, Eugenia .
CHEMICAL RESEARCH IN TOXICOLOGY, 2007, 20 (07) :1031-1037
[34]   New molecular and field evidences for the implication of mycotoxins but not aristolochic acid in human nephropathy and urinary tract tumor [J].
Pfohl-Leszkowicz, Annie ;
Tozlovanu, Mariana ;
Manderville, Richard ;
Peraica, Maja ;
Castegnaro, Marcel ;
Stefanovic, Vladislav .
MOLECULAR NUTRITION & FOOD RESEARCH, 2007, 51 (09) :1131-1146
[35]   Ochratoxin A: An overview on toxicity and carcinogenicity in animals and humans [J].
Pfohl-Leszkowicz, Annie ;
Manderville, Richard A. .
MOLECULAR NUTRITION & FOOD RESEARCH, 2007, 51 (01) :61-99
[36]  
PFOHLLESZKOWICZ A, 1993, IARC SCI PUBL, V1124, P141
[37]  
Shibutani S, 2005, CANCER EPIDEM BIOMAR, V14, p2717S
[38]   Selective toxicity of aristolochic acids I and II [J].
Shibutani, Shinya ;
Dong, Huan ;
Suzuki, Naomi ;
Ueda, Shiro ;
Miller, Frederick ;
Grollman, Arthur P. .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (07) :1217-1222
[39]   Human hepatic and renal microsomes, Cytochromes P450 1A1/2, NADPH:Cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer [J].
Stiborová, M ;
Frei, E ;
Hodek, P ;
Wiessler, M ;
Schmeiser, HH .
INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (02) :189-197
[40]   Perspective: Ochratoxin A is not a genotoxic carcinogen [J].
Turesky, RJ .
CHEMICAL RESEARCH IN TOXICOLOGY, 2005, 18 (07) :1082-1090